172
staff
LaQuandra S. Nesbitt
LaQuandra S. Nesbitt is a board-certified family physician with over a decade of experience leadi
ng population health initiatives in governmental public health agencies.
+ Read More
staff
Megan Ranney, MD
Megan L. Ranney, MD, is the dean of the Yale School of Public Health and C-EA Winslow Professor o
f Public Health at Yale University.
+ Read More
staff
Michelle Longmire
Dr. Michelle Longmire is mission-driven to accelerate the development of new therapies for diseas
e as the founder and Chief Executive Officer of Medable. A Stanford-trained physician-scientist, Dr.
+ Read More
staff
Debi Brooks
Deborah W. Brooks is Chief Executive Officer (CEO) and Co-Founder of The Michael J. Fox Foundatio
n for Parkinson's Research (MJFF). Ms. Brooks launched MJFF with Michael J. Fox in 2000 and served as founding CEO until 2007.
+ Read More
staff
Christopher Austin
Christopher Austin, MD, is a CEO-partner at Flagship Pioneering in Cambridge, MA, and CEO of Vesa
lius Therapeutics, one of Flagship’s franchise companies that is commercializing a platform to systematically develop treatments for common diseases.
+ Read More
staff
Micah Rabin
Micah Rabin is a research intern with the Research Department at the Milken Institute. She suppor
ts the department’s research portfolio in international finance.
+ Read More
staff
Sarah Sandler
Sarah Sandler is the executive director of business and program development at the Milken Institu
te and oversees fundraising strategies across Institute events and programs.
+ Read More
person
Susan Guthrie
staff
Holly Freishtat
Holly Freishtat is the senior director of Feeding Change at the Milken Institute.
report
Global Opportunity Index 2022: White Paper
The Global Opportunity Index assesses countries' attractiveness to international investors using a
combination of economic, financial, institutional, and regulatory factors.
+ Read More
report
Global Opportunity Index 2022: Focus on Emerging Southeast Asia
This report uses the 2022 Global Opportunity Index (GOI) and its various categories to examine the
attractiveness of emerging Southeast Asia as a foreign investment destination—especially when compared to other emerging markets and developing economies
+ Read More
report
Strengthening the Biomedical Innovation Ecosystem: A Scorecard for System Assessment
As patients, we often evaluate our interactions within the "system" of biomedical innovation with a
simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and available, how the
+ Read More